List of Excipients in Branded Drug ANTIZOL

« Back to Dashboard

Antizol Fomepizole Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Antizol is an intravenous fomepizole product used to inhibit alcohol dehydrogenase in patients with suspected or confirmed methanol or ethylene glycol poisoning. Its commercial opportunity is driven less by formulation complexity than by emergency availability, hospital stocking, supply reliability, vial economics and differentiated delivery formats. The core product is a simple aqueous solution with a narrow excipient profile, which limits formulation-patent opportunities but creates room for ready-to-use presentations, improved packaging and supply-chain services.

What is Antizol and how is fomepizole administered?

Antizol contains fomepizole, a small-molecule alcohol dehydrogenase inhibitor. The U.S. product is supplied as a concentrated intravenous solution requiring dilution before infusion. FDA labeling identifies the product as fomepizole injection, 1 g/mL, for intravenous use.[1]

Attribute	Antizol
Active ingredient	Fomepizole
Therapeutic use	Methanol and ethylene glycol poisoning
Route	Intravenous infusion after dilution
Strength	1 g/mL
Dosage form	Sterile injectable solution
Administration setting	Emergency departments, intensive-care units, poison centers and hospitals
Pharmacologic class	Alcohol dehydrogenase inhibitor
FDA product type	Small-molecule prescription drug
U.S. regulatory pathway	NDA product
Biosimilar relevance	None
Primary competitive products	Generic fomepizole injections and hospital-compounded alternatives

The labeled dosing regimen begins with a 15 mg/kg loading dose, followed by weight-based maintenance doses. Dosing intervals change during hemodialysis because fomepizole is dialyzable.[1] This dosing pattern creates a commercial advantage for products that reduce calculation, preparation and administration errors.

What excipients are used in Antizol?

Antizol’s formulation is commercially attractive because it uses a limited excipient system. The labeled product is an aqueous fomepizole injection and is diluted before administration in compatible intravenous fluids, including dextrose 5% injection, 0.9% sodium chloride injection or lactated Ringer’s injection.[1]

The formulation strategy has four practical characteristics:

1. It avoids a complex solvent system.
2. It minimizes excipient-related toxicity in acutely poisoned patients.
3. It permits dilution into standard hospital fluids.
4. It shifts most handling requirements to the hospital pharmacy or emergency department.

The principal formulation controls are pH, concentration, sterility, particulate burden, container compatibility and stability after dilution. FDA labeling requires visual inspection of the diluted solution before administration and specifies dilution and storage conditions.[1]

What excipient risks matter for fomepizole injection?

The main excipient and presentation risks are operational rather than therapeutic.

Risk area	Commercial implication
pH control	Can affect tolerability, stability and container compatibility
Dilution stability	Determines whether pharmacies can prepare doses in advance
Container adsorption or extractables	Relevant to glass, elastomeric closures and polymer bags
Particulates	Critical for emergency injectable products
Preservatives	Avoidance may support use in critically ill patients
Osmolality	Relevant to peripheral versus central administration decisions
Storage after dilution	Affects pharmacy workflow and waste
Vial size	Determines wastage for weight-based dosing

Because fomepizole is administered in emergency settings, a formulation with fewer excipients can be positioned as easier to evaluate for compatibility and less exposed to excipient-related contraindications. The commercial value is strongest when the product is supplied with validated dilution instructions and clear beyond-use information.

What formulations are protected by Antizol patents?

Publicly available FDA product information does not indicate a commercially significant active U.S. patent estate around the basic Antizol fomepizole injection formulation. The product’s primary protection historically came from regulatory approval, brand recognition, hospital distribution and market scarcity rather than from a technically complex excipient platform.

How many patents cover Antizol?

No active Orange Book patent protection should be assumed for the basic Antizol product without a current Orange Book review tied to the relevant NDA and listing date. The FDA Orange Book is the controlling source for patents submitted for approved drug products.[2]

The practical IP position is:

IP category	Assessment
Core fomepizole molecule	Generic small molecule; no meaningful new-molecule exclusivity remaining
Basic injectable formulation	Limited apparent patent differentiation
Dilution instructions	Generally regulatory labeling, not a strong standalone patent barrier
Ready-to-use presentation	Potentially patentable only if supported by novel stability, concentration or container claims
Device-assisted administration	Potential opportunity for combination-product claims
Manufacturing process	Possible trade-secret and process-patent value
Packaging and emergency kit	Potential utility and design protection, but usually narrow
Method of use	Limited room where the method follows established antidote use

A company pursuing Antizol competition should therefore focus on freedom to operate around formulation specifics, container systems, labeling and process claims rather than relying on the absence of a compound patent.

When does Antizol lose exclusivity?

Antizol’s original regulatory exclusivity period has expired. Fomepizole is a mature small-molecule active ingredient, and generic injectable versions have entered the U.S. market. The commercial question is no longer whether the molecule is exclusive. It is whether a supplier can obtain approval, maintain sterile manufacturing capacity and meet emergency hospital demand.

Exclusivity type	Status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the principal current barrier
Pediatric exclusivity	Not a current commercial barrier
Orange Book patent exclusivity	No major active barrier should be presumed
Generic competition	Present
Biosimilar competition	Not applicable

The absence of meaningful exclusivity increases price pressure but does not eliminate commercial opportunity. Hospitals often maintain antidote inventories despite low utilization because treatment delays can be clinically serious and replacement supply may be difficult to obtain.

What is the FDA regulatory status of Antizol?

Antizol is FDA-approved for use in patients with known or suspected methanol or ethylene glycol poisoning. Treatment is typically initiated when clinical findings, exposure history or laboratory results support toxic alcohol poisoning. The label also addresses dosing during hemodialysis and the need for continued treatment until toxic alcohol concentrations and metabolic abnormalities resolve.[1]

What FDA pathway would a new fomepizole product use?

A generic injectable product would generally use an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act, provided it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy applicable FDA requirements.

A differentiated product could require a 505(b)(2) application if it relied on a new formulation, new dosage form, new concentration, new container configuration or modified administration method not covered by an existing reference product.

Development concept	Likely regulatory route
Same 1 g/mL injectable solution	ANDA
Same active ingredient in a prefilled syringe	Potentially ANDA or 505(b)(2), depending on reference product and device
Ready-to-use diluted infusion bag	Likely 505(b)(2) or another FDA-supported pathway
Extended stability after dilution	Could support 505(b)(2) differentiation
Oral fomepizole product	505(b)(2) or NDA, with new clinical and formulation requirements
Combination antidote kit	Combination-product and drug-labeling analysis required

What commercial opportunities exist for Antizol excipients and delivery systems?

The strongest opportunity is not a new excipient. It is reducing preparation steps while preserving chemical stability and emergency usability.

Ready-to-use diluted infusion bags

A manufacturer could develop a validated premixed fomepizole infusion bag in a standard compatible fluid. Advantages would include:

• Lower dose-preparation burden.
• Fewer calculation errors.
• Reduced vial waste.
• Faster treatment initiation.
• Simplified pharmacy staffing requirements.
• More predictable procurement.

The main technical barriers are stability, microbial control, container compatibility, extractables and an economically viable shelf life. The product would need a dosing architecture that accommodates weight-based loading and maintenance doses without creating excessive unused drug.

Prefilled syringes

A prefilled syringe could support rapid loading-dose administration, particularly in emergency departments. It would require assessment of:

• Syringe material and stopper compatibility.
• Fomepizole adsorption.
• Long-term chemical stability.
• Needle or connector compatibility.
• Dose flexibility across patient weights.
• Human-factors validation.
• Whether the syringe is intended for direct administration or further dilution.

Because adult doses vary substantially by body weight, a single fixed-dose syringe may produce waste. Multiple syringe strengths or a cartridge-based system could improve utilization but increase manufacturing and inventory complexity.

Emergency antidote kits

An integrated kit could combine fomepizole vials with compatible diluent, transfer devices, labels and dosing instructions. The kit would not necessarily create strong pharmaceutical exclusivity, but it could produce hospital-contract advantages and reduce medication-preparation time.

Potential kit components include:

• Fomepizole vials.
• Sodium chloride or dextrose diluent.
• Closed-system transfer components.
• Weight-based dosing chart.
• Hemodialysis dosing guide.
• Toxicology consultation contact information.
• Temperature-monitoring indicator.

The kit’s value would come from workflow integration, not from the excipient itself.

Extended-stability formulations

An extended-stability formulation could target hospitals that stock infrequently used antidotes. Longer shelf life would reduce inventory write-offs and improve emergency preparedness. Relevant technical routes include:

• Optimized pH range.
• Low-oxygen headspace control.
• Improved elastomer closure.
• Alternative vial glass or polymer container.
• Light-protective packaging.
• Validated premixed concentration.
• Freeze-thaw and excursion stability.

A stability claim supported by comparative data could form the basis for 505(b)(2) differentiation or a narrower patent position.

How strong is the Antizol patent estate?

The patent estate for the basic fomepizole injection appears weak relative to products protected by complex delivery platforms or active formulation patents. The strongest defensible IP opportunities would likely involve a specific combination of concentration, diluent, container and stability profile.

Potential claim type	Relative strength	Commercial value
Fomepizole molecule	Low	Low
Basic aqueous injection	Low	Low
Specific premixed concentration with stability data	Moderate	Moderate to high
Prefilled syringe configuration	Moderate	Moderate
Container-closure system	Moderate	Moderate
Emergency kit configuration	Low to moderate	Moderate
Manufacturing impurity-control process	Moderate	Moderate
Broad method of treating toxic alcohol poisoning	Low	Low
Hospital procurement or distribution model	Not patent-driven	High operational value

Patent strength would depend on whether the claimed formulation produces an unexpected stability, safety or handling advantage. Broad claims covering “fomepizole in an aqueous solution” would face substantial validity and obviousness risk because the reference product and generic products establish the basic formulation concept.

Which companies are challenging Antizol and competing in fomepizole?

Competition comes primarily from generic injectable manufacturers rather than from biosimilar developers. Fomepizole is not a biologic, so biosimilar pathways do not apply.

The competitive landscape includes:

• The Antizol brand and its commercial successor or current licensee.
• FDA-approved generic fomepizole injection suppliers.
• Hospital pharmacies capable of emergency compounding under applicable rules.
• International suppliers selling fomepizole products outside the United States.
• Potential 505(b)(2) developers pursuing premixed or device-enabled delivery.

Generic competition may not fully commoditize the market because hospital buyers evaluate shortage history, reliability, expiration dating, service levels, unit-dose availability and emergency distribution. Infrequent-use antidotes also have procurement dynamics that differ from high-volume hospital injectables.

What generic entry risks exist for Antizol?

Generic entry creates four main risks for the branded product:

1. Price erosion. Hospital systems can substitute therapeutically equivalent injectable fomepizole products.
2. Contract displacement. Group purchasing organizations may consolidate purchases with fewer suppliers.
3. Formulary substitution. Pharmacy committees may remove the brand where no clinical difference exists.
4. Inventory rationalization. Hospitals may select the lowest-cost supplier that meets minimum stock requirements.

Generic suppliers face their own barriers. Sterile injectable manufacturing has higher regulatory and quality-system requirements than oral solid-dose manufacturing. Small market volume can reduce the incentive to enter, while shortages or discontinuations can rapidly change market share.

What patent litigation affects Antizol?

No major, currently material patent litigation involving a foundational Antizol formulation is evident from the product’s mature generic-market position and the absence of an apparent blocking Orange Book patent estate. The principal legal risks for a new entrant would instead involve:

• ANDA patent certifications, if any listed patents are identified.
• Patent claims covering a specific ready-to-use concentration.
• Device patents on prefilled syringes or transfer systems.
• Trade-secret disputes over manufacturing processes.
• Regulatory exclusivity or reference-product issues.
• Product-liability claims related to dosing, dilution or administration.

A Paragraph IV challenge would become relevant only if an applicant certifies that a listed patent is invalid, unenforceable or will not be infringed. For basic fomepizole injection, the commercial importance of a Paragraph IV pathway appears limited unless a newer differentiated formulation receives Orange Book-listed patents.

Are there licensing opportunities for Antizol?

Licensing opportunities are more likely to involve distribution, manufacturing and delivery technology than the underlying fomepizole molecule.

Attractive licensing models

Model	Value proposition
Regional distribution license	Expands access where toxic alcohol exposure is a recognized emergency risk
Contract manufacturing	Uses an existing sterile injectable facility
Premixed-bag technology license	Shortens development time for a differentiated product
Prefilled-syringe platform license	Adds emergency-department convenience
Hospital antidote portfolio deal	Bundles fomepizole with acetylcysteine, hydroxocobalamin or other antidotes
Government stockpile agreement	Supports predictable demand and preparedness purchasing

A portfolio strategy could pair fomepizole with other emergency antidotes. The commercial rationale is stronger when one sales force, distributor network and hospital contract supports several low-frequency products.

How does Antizol compare with competing antidote products?

Antizol differs from many hospital antidotes because its use is highly protocolized and its dosing depends on body weight and dialysis status.

Product category	Formulation complexity	Main commercial differentiator
Fomepizole injection	Low to moderate	Availability and rapid preparation
Ethanol therapy	High operational variability	Low acquisition cost but difficult monitoring
Acetylcysteine injection	Moderate	Concentration, infusion protocol and reaction management
Hydroxocobalamin	High	Large-volume emergency presentation and supply reliability
Activated charcoal products	Low	Indication, packaging and administration convenience

Fomepizole’s main advantage over ethanol is predictable pharmacology and simpler monitoring. A new product should preserve that advantage while reducing dilution and dosing complexity.

What revenue exposure exists for an Antizol competitor?

Publicly attributable revenue for Antizol alone is generally not disclosed by diversified pharmaceutical companies. Market size is constrained by the low incidence of confirmed toxic alcohol poisoning relative to common emergency medicines. Revenue potential depends on stocking requirements rather than recurring daily use.

A commercial model should therefore measure:

• Number of U.S. hospitals stocking toxicology antidotes.
• Average vial inventory per site.
• Annual replacement volume.
• Expiration-related waste.
• Average selling price per vial.
• Government and poison-center procurement.
• Generic supplier count.
• Shortage frequency.
• Contract win rates.
• Emergency replenishment premiums.

The product can support attractive margins if manufacturing volume is low, supply is reliable and the supplier controls a differentiated delivery format. A commodity vial without supply or workflow differentiation faces stronger price pressure.

What geographic opportunities exist for fomepizole?

The strongest geographic opportunities are jurisdictions with:

• Significant industrial solvent exposure.
• Alcohol adulteration risk.
• Limited toxicology infrastructure.
• Centralized hospital procurement.
• Hemodialysis capacity.
• Government emergency-stockpile programs.

International expansion may require local registration, stability studies, packaging localization, pharmacovigilance infrastructure and a reliable cold-chain or controlled-temperature distribution model. The product’s simple formulation can ease registration, but country-specific antidote procurement systems can lengthen market entry.

Key Takeaways

• Antizol is a mature fomepizole injection product with limited formulation complexity.
• The excipient strategy is based on an aqueous injectable formulation compatible with standard hospital diluents.
• Core molecule and basic formulation patent barriers appear weak; current Orange Book data should control any transaction or launch decision.
• Biosimilar risk does not apply because fomepizole is a small molecule.
• The strongest commercial opportunities are ready-to-use infusion bags, prefilled syringes, emergency kits and extended-stability presentations.
• Sterile manufacturing, stability validation and reliable supply are more important barriers than compound patents.
• Generic competition is present, but low-frequency antidote procurement can preserve value for dependable suppliers.
• A differentiated product would likely require an ANDA or 505(b)(2) strategy depending on the formulation and delivery system.
• Licensing value is highest in distribution, sterile manufacturing, device technology and hospital-antidote portfolios.
• Revenue depends on hospital stocking, replacement cycles, government procurement and supply reliability rather than high prescription volume.

FAQs About Antizol Excipient and Commercial Strategy

Is propylene glycol used in Antizol?

The FDA product labeling should be used to determine the current inactive-ingredient composition. The commercial formulation should not be assumed to contain propylene glycol without confirmation from the applicable label or approved product record.[1]

Can fomepizole be sold as a ready-to-use infusion?

A ready-to-use infusion could be developed if the sponsor establishes concentration, container compatibility, sterility, stability, labeling and administration requirements. The regulatory pathway would depend on the proposed product and reference-product relationship.

Does Antizol have an orphan-drug monopoly?

Any historical orphan-drug protection would not be treated as a current commercial barrier for mature fomepizole products without confirmation from FDA exclusivity records. Generic fomepizole products are already commercially relevant.

What is the best excipient for improving fomepizole stability?

No single excipient can be selected without compatibility and stability data. For this product, container closure, pH control, oxygen exposure and dilution conditions may have greater impact than adding a new excipient.

Is oral fomepizole a commercial opportunity?

An oral fomepizole product could reduce intravenous preparation requirements, but it would require evaluation of absorption, dosing reliability, emergency use, poisoning severity, regulatory classification and clinical positioning. Its commercial value would depend on demonstrating a meaningful advantage over established intravenous treatment.

References

1. U.S. Food and Drug Administration. (2024). Antizol (fomepizole) injection, prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. National Library of Medicine. (2024). DailyMed: Fomepizole injection product labeling.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Generic drug products.